Komori
Other Disclosures4586Medrx Co.,Ltd.Pharmaceuticals

Notice of a U.S. patent allowance for Bondlido

The company received a notice of patent allowance from the U.S. Patent and Trademark Office for manufacturing process technology that achieves uniformity and stability for Bondlido. The patent is valid through 2040.

Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
2040
Through 2040 (patent validity period)
Wording
Conditional
How definitive the wording is.

Announced details

Bondlido (lidocaine-containing patch)
Applicable field (uses covered by this announcement)

Treatment of postherpetic neuralgia in adults

What the company reported numerically
Quantitative Effects

The disclosure states that Bondlido is expected to achieve market penetration because it causes less skin irritation than Lidoderm, offers superior adhesion, and retains its adhesion during movement.

Relationship between the counterparty and the company
Medrx Co.,Ltd.4586
Relationship with the Company

Agency with which the company has filed a patent application

CounterpartyU.S. Patent and Trademark Office (USPTO)

U.S. agency responsible for patents and trademarks

Registration number and expiry date

U.S. patent allowance. Valid through 2040. Registration number and registration date: Not disclosed

Impact on Business Performance

There is no change to the current fiscal year's earnings forecast, but the company believes the patent will contribute to improved performance over the medium to long term.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

IQVIA

Announced details
ItemDetails
Names of Products / Services CoveredBondlido (lidocaine-containing patch)
CounterpartyU.S. Patent and Trademark Office (USPTO)
Counterparty overviewU.S. agency responsible for patents and trademarks
Relationship with the CompanyAgency with which the company has filed a patent application
Applicable areaTreatment of postherpetic neuralgia in adults
Registration number and expiry dateU.S. patent allowance. Valid through 2040. Registration number and registration date: Not disclosed
Quantitative EffectsThe disclosure states that Bondlido is expected to achieve market penetration because it causes less skin irritation than Lidoderm, offers superior adhesion, and retains its adhesion during movement.
Impact on Business PerformanceThere is no change to the current fiscal year's earnings forecast, but the company believes the patent will contribute to improved performance over the medium to long term.
SourceIQVIA
Items this document does not state (9)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To protect the company's proprietary manufacturing process technology for achieving uniformity and stability for Bondlido.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of a U.S. patent allowance for Bondlido | Medrx Co.,Ltd. (4586) timely disclosure | Komori